From GlobeNewswire: 2024-08-14 21:00:00

Arcutis Biotherapeutics, Inc. reported significant growth in second-quarter net product revenues for their ZORYVE franchise, with sales reaching $30.9 million. They also announced an amended $200 million term-loan to increase financial flexibility and strategic options. The company is pleased with sales growth and prudently managing expenses, positioning them well for continued investment in growth.

ZORYVE cream and foam continue to gain traction in the market, with over 252,000 prescriptions filled for plaque psoriasis and positive feedback from patients and physicians. The FDA recently approved ZORYVE cream for atopic dermatitis, with coverage by large PBMs. ZORYVE foam for seborrheic dermatitis is also performing well, with over 98,000 prescriptions filled so far.

Arcutis is also advancing their ARQ-255 and ARQ-234 programs for alopecia areata and atopic dermatitis, respectively, with key milestones expected in the coming years. Recent corporate highlights include FDA approvals for ZORYVE cream and a co-promotion agreement with Kowa Pharmaceuticals to expand the marketing efforts of their products. Financially, they reported product revenues of $30.9 million for Q2 ’24, a significant increase from $4.8 million in 2023.

Overall, Arcutis Biotherapeutics, Inc. is experiencing strong sales growth and strategic advancements in their product offerings. With positive feedback from the market, FDA approvals, and financial flexibility from their loan amendment, the company is well-positioned for continued success and growth in the immuno-dermatology sector.



Read more at GlobeNewswire:: CORRECTION – Arcutis Announces Second Quarter 2024